PBH — Prestige Consumer Healthcare Inc. stock price, charts and financials

QT35Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc. (NYSE: PBH) is a Healthcare company in the Medical - Distribution industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
52.00
+0.08+0.15%
PBHQT35Prestige Consumer Healthcare Inc.·NYSE
52.00+0.15%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E13.30EPS (ttm)3.91Insider Own2.13%Shs Outstand47.37MPerf Week0.54%
Market Cap2.46BForward P/E10.61EPS next Y4.90Insider Trans-0.32%Shs Float46.70MPerf Month6.43%
Enterprise Value3.44BPEG2.03EPS next Q-Inst Own-Short Float6.61%Perf Quarter-5.98%
Income190.00MP/S2.26EPS this Y16.04%Inst Trans-Short Ratio4.51Perf Half Y-20.54%
Sales1.09BP/B1.30EPS next Y8.06%ROA5.36%Short Interest3.09MPerf YTD-15.71%
Book/sh39.85P/C38.49EPS next 5Y6.56%ROE10.29%52W High75.31 -30.95%Perf Year-29.46%
Cash/sh1.35P/FCF9.36EPS past 3/5Y- 3.77%ROIC6.65%52W Low42.62 22.01%Perf 3Y-20.00%
Dividend Est.-EV/EBITDA10.35Sales past 3/5Y-1.17% 2.92%Gross Margin53.96%Volatility3.05% 3.41%Perf 5Y-1.27%
Dividend TTM-EV/Sales3.15EPS Y/Y TTM-8.86%Oper. Margin28.42%ATR (14)1.88Perf 10Y-3.24%
Dividend Ex-DateSep 27, 2018Quick Ratio2.25Sales Y/Y TTM-4.31%Profit Margin17.48%RSI (14)59.20Recom2.47
Dividend Gr. 3/5Y- 8.73%Current Ratio3.57EPS Q/Q0.82%SMA204.41%Beta0.33Target Price81.67
Payout0.00%Debt/Eq0.55Sales Q/Q-5.05%SMA507.35%Rel Volume1.52Prev Close51.92
Employees890LT Debt/Eq0.55EarningsAug 06SMA200-10.08%Avg Volume703.12KPrice52.00
IPO DateFeb 10, 2005Option/ShortYes / YesEPS/Sales Surpr.-11.51% -4.09%Net Debt/EBITDA2.96Volume1,072,252Change0.15%
Analyst Ratings
DateActionAnalystRatingTarget
May-14-26DowngradeOppenheimerOutperformPerform
Oct-27-25ReiteratedJefferiesHold$71
Nov-05-24ReiteratedCanaccord GenuityBuy$71$86
Jun-21-24UpgradeDA DavidsonNeutralBuy$93
Nov-17-22ReiteratedCanaccord GenuityBuy$71
May-10-22UpgradeJefferiesHoldBuy
May-09-22UpgradeOppenheimerPerformOutperform
Aug-07-20DowngradeDA DavidsonBuyNeutral
Mar-26-20UpgradeJefferiesHoldBuy
Mar-19-20UpgradeDA DavidsonNeutralBuy
Latest News
Jul-30-26
Jul-27-26
Jul-23-26
Jul-20-26
Jul-19-26
Jul-13-26
Jul-06-26
Jul-03-26
Jun-30-26
Company

Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2026
3/31/2026
FY 2025
3/31/2025
FY 2024
3/31/2024
FY 2023
3/31/2023
FY 2022
3/31/2022
FY 2021
3/31/2021
FY 2020
3/31/2020
FY 2019
3/31/2019
Total Revenue1,0891,0891,1381,1251,1281,087943963976
Cost of Goods Sold Incl. D&A501514503501502466396411420
Gross Profit587575634624625621547552556
Selling, General and Administrative Excl. Other265265264259252265224236233
Research and Development
000000000
Other Operating Expense120342339626262527
Operating Income309309337342-2233029729168
Interest Expense4242486769648297105
Unusual Expense
Non-Operating Income (Expense)-10-10-51-2-3-11-30
Net Income Before Taxes258257284276-94262204191-38
Income Taxes67677067-12573949-2
Consolidated Net Income190190215209-82205165142-36
Net Income From Continuing Operations190190215209-82205165142-36
Net Income190190215209-82205165142-36
EPS (Recurring)3.943.934.324.21-1.654.093.282.81-0.69
EPS (Basic, Before Extraordinaries)3.943.934.324.21-1.654.093.282.81-0.69
EPS (Diluted)3.913.914.294.17-1.654.043.252.78-0.69
EBITDA332331362374835931732599
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio13.3015.1620.0417.4013.1013.5613.19
Price To Sales Ratio2.242.613.783.222.782.442.341.941.59
Gross Margin53.9052.8055.7155.4755.4157.1358.0157.3256.97
Operating Margin28.3728.3729.6130.40-1.9530.3631.5030.226.97
Net Margin17.4517.4518.8918.58-7.2718.8617.5014.75-3.69
Shares Outstanding474850505050505152
Market Capitalization2,4442,8454,2993,6283,1322,6472,2041,8711,555
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$92.82$79.43$66.04$52.65$39.26 Close Price0.00K55.30K110.59K165.89K221.19KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Zerillo JeffreySenior VP OperationsMay 11 '26Sale52.2835118,35041,810May 12
Zerillo JeffreySenior VP OperationsMay 07 '26Sale54.3630516,58042,161May 11
Zerillo JeffreySenior VP OperationsMay 05 '26Sale55.061,55385,51442,820May 07
Zerillo JeffreySenior VP OperationsFeb 11 '26Sale65.931,00065,93041,048Feb 13
Zerillo JeffreySenior VP OperationsDec 01 '25Sale60.0028116,86042,048Dec 02
Zerillo JeffreySenior VP OperationsNov 28 '25Sale60.0071943,14042,329Dec 02
BYOM JOHN EDirectorNov 25 '25Sale59.353,000178,05051,594Nov 26
Fritz Mary BethSVP Quality & RegulatoryMar 10 '25Sale90.001,678151,02017,157Mar 12
Fritz Mary BethSVP Quality & RegulatoryMar 03 '25Option Exercise44.336,297279,14625,132Mar 05
Fritz Mary BethSVP Quality & RegulatoryMar 03 '25Sale85.396,297537,70118,835Mar 05
Mekhail AdelEVP, Marketing & SalesFeb 11 '25Option Exercise49.5311,083548,93524,048Feb 13
Mekhail AdelEVP, Marketing & SalesFeb 11 '25Sale86.5511,083959,27118,365Feb 13
Lombardi Ronald M.Chief Executive OfficerNov 19 '24Option Exercise56.6210,875615,774326,614Nov 21
Lombardi Ronald M.Chief Executive OfficerNov 19 '24Sale82.6010,875898,241320,952Nov 21
Lombardi Ronald M.Chief Executive OfficerNov 18 '24Option Exercise56.7482,2374,666,226369,464Nov 19
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.